"Tetrahydrouridine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An inhibitor of nucleotide metabolism.
| Descriptor ID |
D013767
|
| MeSH Number(s) |
D03.383.742.680.852.800 D13.570.685.852.800 D13.570.800.892.800
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Tetrahydrouridine".
Below are MeSH descriptors whose meaning is more specific than "Tetrahydrouridine".
This graph shows the total number of publications written about "Tetrahydrouridine" by people in this website by year, and whether "Tetrahydrouridine" was a major or minor topic of these publications.
![]()
To see the data from this visualization as text,
click here.
Below are the most recent publications written about "Tetrahydrouridine" by people in Profiles.
-
A plant pentatricopeptide repeat protein with a DYW-deaminase domain is sufficient for catalyzing C-to-U RNA editing in vitro. J Biol Chem. 2020 03 13; 295(11):3497-3505.
-
Activity of 2',2'-difluorodeoxycytidine (Gemcitabine) against human tumor colony forming units. Anticancer Drugs. 1992 Apr; 3(2):143-6.
-
Effect of tetrahydrouridine and deoxytetrahydrouridine on the interaction between 2'-deoxycytidine and 1-beta-D-arabinofuranosylcytosine in human leukemia cells. Leuk Res. 1991; 15(4):205-13.
-
Modulation of deoxynucleotide metabolism by the deoxycytidylate deaminase inhibitor 3,4,5,6-tetrahydrodeoxyuridine. Biochem Pharmacol. 1989 Nov 15; 38(22):4115-21.
-
Effect of tetrahydrouridine on the clinical pharmacology of 1-beta-D-arabinofuranosylcytosine when both drugs are coinfused over three hours. Cancer Res. 1988 Mar 01; 48(5):1337-42.
-
Deoxycytidine stimulates the in vitro growth of normal CFU-GM and reverses the negative regulatory effects of acidic isoferritin and prostaglandin E1. Blood. 1986 Nov; 68(5):1136-41.
-
Influence of tetrahydrouridine on the pharmacokinetics of intrathecally administered 1-beta-D-arabinofuranosylcytosine. Cancer Res. 1982 May; 42(5):1736-9.